Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Total Liabilities (2022 - 2025)

Historic Total Liabilities for Immunocore Holdings (IMCR) over the last 4 years, with Q3 2025 value amounting to $705.9 million.

  • Immunocore Holdings' Total Liabilities fell 12.38% to $705.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $705.9 million, marking a year-over-year decrease of 12.38%. This contributed to the annual value of $648.8 million for FY2024, which is 18436.0% up from last year.
  • Latest data reveals that Immunocore Holdings reported Total Liabilities of $705.9 million as of Q3 2025, which was down 12.38% from $693.9 million recorded in Q2 2025.
  • Immunocore Holdings' 5-year Total Liabilities high stood at $706.8 million for Q3 2024, and its period low was $187.9 million during Q4 2022.
  • Moreover, its 4-year median value for Total Liabilities was $649.5 million (2025), whereas its average is $568.9 million.
  • In the last 5 years, Immunocore Holdings' Total Liabilities skyrocketed by 18436.0% in 2024 and then fell by 12.38% in 2025.
  • Quarter analysis of 4 years shows Immunocore Holdings' Total Liabilities stood at $187.9 million in 2022, then grew by 21.45% to $228.2 million in 2023, then surged by 184.36% to $648.8 million in 2024, then increased by 8.81% to $705.9 million in 2025.
  • Its last three reported values are $705.9 million in Q3 2025, $693.9 million for Q2 2025, and $649.5 million during Q1 2025.